Your browser doesn't support javascript.
loading
Liraglutide targets the gut microbiota and the intestinal immune system to regulate insulin secretion.
Charpentier, Julie; Briand, Francois; Lelouvier, Benjamin; Servant, Florence; Azalbert, Vincent; Puel, Anthony; Christensen, Jeffrey E; Waget, Aurélie; Branchereau, Maxime; Garret, Céline; Lluch, Jérome; Heymes, Christophe; Brousseau, Emmanuel; Burcelin, Rémy; Guzylack, Laurence; Sulpice, Thierry; Grasset, Estelle.
Afiliación
  • Charpentier J; Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.
  • Briand F; Unité Mixte de Recherche (UMR) 1048, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier (UPS), Team 2: 'Intestinal Risk Factors Diabetes, Dyslipidemia', 31432, Toulouse Cedex 4, France.
  • Lelouvier B; PHYSIOGENEX SAS Prologue Biotech, 516 Rue Pierre et Marie Curie, 31670, Labège Innopole, France.
  • Servant F; Vaiomer, Prologue Biotech, 516 Rue Pierre et Marie Curie, 31670, Labège Innopole, France.
  • Azalbert V; Vaiomer, Prologue Biotech, 516 Rue Pierre et Marie Curie, 31670, Labège Innopole, France.
  • Puel A; Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.
  • Christensen JE; Unité Mixte de Recherche (UMR) 1048, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier (UPS), Team 2: 'Intestinal Risk Factors Diabetes, Dyslipidemia', 31432, Toulouse Cedex 4, France.
  • Waget A; Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.
  • Branchereau M; Unité Mixte de Recherche (UMR) 1048, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier (UPS), Team 2: 'Intestinal Risk Factors Diabetes, Dyslipidemia', 31432, Toulouse Cedex 4, France.
  • Garret C; Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.
  • Lluch J; Unité Mixte de Recherche (UMR) 1048, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier (UPS), Team 2: 'Intestinal Risk Factors Diabetes, Dyslipidemia', 31432, Toulouse Cedex 4, France.
  • Heymes C; Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.
  • Brousseau E; Unité Mixte de Recherche (UMR) 1048, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier (UPS), Team 2: 'Intestinal Risk Factors Diabetes, Dyslipidemia', 31432, Toulouse Cedex 4, France.
  • Burcelin R; Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.
  • Guzylack L; Unité Mixte de Recherche (UMR) 1048, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier (UPS), Team 2: 'Intestinal Risk Factors Diabetes, Dyslipidemia', 31432, Toulouse Cedex 4, France.
  • Sulpice T; Vaiomer, Prologue Biotech, 516 Rue Pierre et Marie Curie, 31670, Labège Innopole, France.
  • Grasset E; Vaiomer, Prologue Biotech, 516 Rue Pierre et Marie Curie, 31670, Labège Innopole, France.
Acta Diabetol ; 58(7): 881-897, 2021 Jul.
Article en En | MEDLINE | ID: mdl-33723651
AIMS: Liraglutide controls type 2 diabetes (T2D) and inflammation. Gut microbiota regulates the immune system and causes at least in part type 2 diabetes. We here evaluated whether liraglutide regulates T2D through both gut microbiota and immunity in dysmetabolic mice. METHODS: Diet-induced dysmetabolic mice were treated for 14 days with intraperitoneal injection of liraglutide (100 µg/kg) or with vehicle or Exendin 4 (10 µg/kg) as controls. Various metabolic parameters, the intestinal immune cells were characterized and the 16SrDNA gene sequenced from the gut. The causal role of gut microbiota was shown using large spectrum antibiotics and by colonization of germ-free mice with the gut microbiota from treated mice. RESULTS: Besides, the expected metabolic impacts liraglutide treatment induced a specific gut microbiota specific signature when compared to vehicle or Ex4-treated mice. However, liraglutide only increased glucose-induced insulin secretion, reduced the frequency of Th1 lymphocytes, and increased that of TReg in the intestine. These effects were abolished by a concomitant antibiotic treatment. Colonization of germ-free mice with gut microbiota from liraglutide-treated diabetic mice improved glucose-induced insulin secretion and regulated the intestinal immune system differently from what observed in germ-free mice colonized with microbiota from non-treated diabetic mice. CONCLUSIONS: Altogether, our result demonstrated first the influence of liraglutide on gut microbiota and the intestinal immune system which could at least in part control glucose-induced insulin secretion.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Liraglutida / Microbioma Gastrointestinal / Secreción de Insulina / Sistema Inmunológico / Mucosa Intestinal Límite: Animals Idioma: En Revista: Acta Diabetol Asunto de la revista: ENDOCRINOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Liraglutida / Microbioma Gastrointestinal / Secreción de Insulina / Sistema Inmunológico / Mucosa Intestinal Límite: Animals Idioma: En Revista: Acta Diabetol Asunto de la revista: ENDOCRINOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Alemania